S_ry A major problem in cytostatic treatment of many tumours is the deveklopent of multidrug resistance (MDR4). This is most often accompanied by the ovrexpon of a membrane transport protein, P-glycoprotein, and its encoding mRNA. In order to reverse the resistant phenotype in cell cultures, we constructed a specific hammerhead ribozyme possessing catalytic activity that cleaves the 3'-end of the GUC sequence in codon 880 of the mdrl mRNA. We demonstrated that the constructed ribozyme is able to cleave a reduced substrate mdrl mRNA at the GUC position under physiolgical conditions in a cell-free system. A DNA sequence encoding the ribozyme gene was then incorporated into a mammahan expression vector (pHPAPr-l neo) and transfected into the human pancreatic carcinoma cell line EPP85-181RDB, which is resistant to daunorubicin and expresses the MDR phenotype. The expressed ribozyme decreased the level of mdrl mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell's resistance to daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more resistant than the parental cell line.
Chemotherapy has proved to be an effective strategy against malignant tumours. However, during therapy many tumours become resistant not only to the specific cytostatic drug with which they are being treated and to which they were initially sensitive, but also to many other compounds (cross-resistance). This multidrug resistance is often mediated by the enhanced expression of the mdrl gene Ueda et al., 1987) . The product of the murl gene is a glycoprotein (P-Gp) of 170 kDa molecular weight which is found concentrated in the plasma membrane (Juliano & Ling, 1976; Kartner et al., 1983 Kartner et al., , 1985 . The overexpression of P-Gp is accompanied by the enhanced synthesis of the 4.5 kb mdrl mRNA . P-Gp has a total length of 1,280 amino acids, with two ATP binding sites. Furthermore, it has drug-binding properties (Cornwell et al., 1987) and may function as an energy-dependent efflux pump . This is a reason why resistant tumour cells show reduced drug accumulation, thus allowing their survival at otherwise toxic drug concentrations (Endicott & Ling, 1989) .
Ribozymes have nucleolytic activity and are able to cleave specific RNA sequences (Cech & Bass, 1986) . Hammerhead ribozymes are able to cleave the 3'-end of the triplet GUX (where X is C, A or U) in RNA molecules. The central core of the hammerhead is responsible for the cleavage reaction, whereas the flanking sequences mediate specific binding to the target RNA (Uhlenbeck, 1987; Haseloff & Gerlach, 1988; Cameron & Jennings, 1989) . Since such ribozymes can be targeted to specific RNA sequences, they have proved to be useful tools for inhibiting undesired gene expression. In tissue culture assays, specific hamrhead ribozymes were able to cleave human immunodeficiency virus type 1 (Sarver et al., 1990) , c-fos and H-ras . In vitro trancrtion and purificatin of the ribozyme and target RNA This was performed as described by Krupp (1988 (Gunning et al., 1987) , which contains a P-actin promoter sequence and a gene for neomycin selection. The plasmid containing the ribozyme sequence pHPAPr-I neo/mdr-Rb was constructed according to the protocol described by Kashani-Sabet et al. (1992) .
Cell lines
The primary culture of human pancreatic carcinoma cell line EPP85-181P was previously established as described elsewhere (Dietel et al., 1988 (Dietel et al., , 1990 (Dietel et al., 1990 Northern blot analysis (see below) and by immunocytochemistry against the P-glycoprotein using the monoclonal antibody C-219) (Centocor (Dietel, 1991) .
Northern blot analisis Total RNA was extracted using the acid guanidinium thiocyanate method (Chomczynski & Sacchi, 1987 with the plasmid pHPAPr-l neo/mdr-Rb was carried out by electroporation as described by Kashani-Sabet et al. (1992) , using an IBI Gene Zapper. Transfection with the plasmid pHPAPr-l neo without the ribozyme sequence served as a negative control. This excludes the possibility that reversion of the mdr phenotype might be a consequence of plasmid incorporation. Cell clones were selected by adding 500 yg ml-' G418 (geneticin sulphate) for 4 weeks to the cell culture medium. The transfected cell clones were charactenrsed as descnrbed above.
Monolayer proliferation assay to assess ICs As a functional assay to determine daunorubicin resistance, the cell lines and the selected clones were subjected to a monolayer proliferation assay as described by Dietel et al. (1990 
Immunocytochemical analjsis
This is shown in Figure 3 . Neither the parent cell line EPP85-18 1P (Figure 3c ), which is sensitive to daunorubicin, nor the clones containing the ribozyme exhibited P-glycoprotein immunoreactivity using the monoclonal antibody C-2 19 ( Figure 3b ). P-glycoprotein could be detected in the resistant cell line EPP85-181RDB and in the control clone (EPP85-181 RDB/Vec), which contained the vector alone (Figure 3a and d).
Monolayer proliferation assa) The results of the monolayer proliferation assay are shown in Figure 4 . The resistant cell line EPP85-181RDB, which has an IC5o of 12 iLg ml-', is approximately 1,600-fold more resistant to daunorubicin than the parental EPP85-181P cell line, which has an IC50 of about 0.0075 igml-'. In both clones (EPP85-181RDB-Rbl/2) that contain the ribozyme the resis- clones containing the ribozyme were decreased from about 12 Lg ml-' daunorubicin in the resistant cell line to 0.03 tLg ml-' and 0.04 gg ml-' respectively. The expression of the ribozyme reduced the resistance from 1,600-fold to about 5.3-fold. This is a reduction of the resistance to daunorubicin of about 300-fold. The clone which contained the expression vector (EPP85-181RDB/Vec) continued to be as resistant to daunorubicin as the original resistant cell line EPP85-181 RDB. The reversal of resistance achieved with doxorubicin and vincristine is in the same range as that achieved with daunorubicin.
A hammerhead ribozyme was designed to cleave the 3'-end of the GUC triplet in exon 21 of the mdrl mRNA in P-Gp-positive human pancreatic carcinoma cells exhibiting the MDR phenotype. The target site was chosen between the two ATP binding sites, which may be important for the function of the P-Gp as an ATP-dependent pump (Cornwell et al., 1987) . Prior to testing the ribozyme in tissue culture, we investigated its ability to cleave the target sequence of the mdrl mRNA in a cell-free system. Although in this test a relatively high ratio of ribozyme to substrate (4:1) was employed, the catalytic activity of the ribozyme is sufficient to cleave at smaller ratios (up to 1:4, data not shown). A mammalian expression vector containing the 43 bp DNA sequence that encodes the mdrl ribozyme was transfected into the pancreatic carcinoma cell line EPP85-181RDB. Two cell clones that expressed the ribozyme (EPP85-181RDB-Rbl/2) were isolated. The amount of mdrl mRNA was reduced to such an extent that it was no longer detectable; at the same time, no P-Gp formation was observed. The overexpression of mdrl mRNA is inhibited by the ribozyme and therefore only a very small amount of mdrl mRNA is probably still present and cannot be detected by Northern blot analysis. In contrast, using the RT-PCR technique, the ribozyme-expressing cell clones grown in 0.0125p1gml-daunorubicin-supplemented medium gave a clear MDRspecific signal (not shown). The expression of the ribozyme resulted in a 300-fold reduction in resistance. Whether the reduction of resistance is the result of a high level of ribozyme expression and/or a high ribozyme cleavage efficiency (or antisense function) in the transformed cell clones remains to be studied.
We were able to determine that upon increasing the concentration of daunorubicin in the medium, the expression of the mdrl mRNA (Figure 2 ), the formation of P-glycoprotein and the cells' resistance was increased (data not shown). The extent of the reduction in resistance in our cell line EPP85-181RDB-Rbl/2 suggests that P-glycoprotein is in this case the major mechanism of resistance. (Sarver et al., 1990) and as tools to help study gene expression as well as to confer malignant phenotype (Scanlon et al., 1991; Kashani-Sabet et al., 1992) . Our experiments show that our ribozyme can be targeted to inhibit the expression of the mdrl gene, and may represent a potential help in an additional strategy of cancer treatment. In the last few years it has been demonstrated that modified bases of the ribozymes make them resistant to nuclease degradation and very stable in serum (Pieken et al., 1991; Paolella et al., 1992) . We intend to investigate the possibility of applying a modified ribozyme directly to the cell culture, thus increasing its usefulness for therapeutic applications.
We would like to thank Dr Guido Krupp 
